Navigation Links
Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
Date:2/23/2009

y resolution of fever. Viral shedding (time weighted change from baseline in viral titer) was reduced by a median of -2.0 logs for peramivir 200 mg, -2.1 logs for peramivir 400 mg, and -1.9 logs for oseltamivir (p=0.908). There was no mortality in the primary efficacy population, and there were no clinical relapses. Patients were discharged from hospital after a median of 4.0 days for peramivir 200 mg, 3.8 days for peramivir 400 mg, and 4.0 days for oseltamivir (p=0.994). The median number of days required for resumption of usual activities was 8.8 days for peramivir 200 mg, 9.0 days for peramivir 400 mg, and 13.7 days for oseltamivir (p=0.276).

"We are encouraged by these data and are currently working with the U.S. Food and Drug Administration to determine the next steps for peramivir as a treatment for patients hospitalized with influenza," said Dr. William P. Sheridan, BioCryst's Chief Medical Officer. "There are currently no approved treatment options for the 200,000 patients hospitalized for influenza each year and we believe peramivir may be a potential new option for these patients."

"This study greatly enhances our knowledge of the clinical and virologic course of influenza in hospitalized patients who receive neuraminidase inhibitors," stated Dr. Ison. "Peramivir holds promise as a once-daily intravenous treatment that is safe and potentially effective for use in patients with acute influenza, including the elderly and patients with underlying cardiac or pulmonary disease."

The multicenter, randomized, double-blind, double-dummy, active-controlled, Phase 2 study enrolled 137 patients, who tested positive by rapid antigen test (RAT) for influenza and had one or more criteria for hospitalization, namely: age greater than or equal to 60 years, chronic lung disease, congestive heart failure, diabetes mellitus, low oxygen saturation, low blood pressure, or severity of illness requiring supportive care. O
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
4. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
5. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
6. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
9. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... REYKJAVIK, Iceland, July 1 The ... several new common,single-letter variants in the sequence of the human ... a multinational consortium of scientists,led by a team from deCODE ... 50,000 patients and control participants from fourteen countries.,It is published ...
... announces that it has reached the halfway mark (1,600 patients) ... G auging R esponsiveness with A V erifyNow(R) ... nd S afety). The trial is specifically designed ... for patients who are poor responders to clopidogrel (Plavix(R)). ...
Cached Medicine Technology:deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian ... to think outside the bra. She doesn’t try to hide ... awareness about women’s other lady parts. , "We have won ... color pink and everybody knows what you’re talking about,” Jess-Huff ... has not been won when it comes to gynecologic cancers. ...
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Message Brokering, SOA integration, and Complex-Event Processing (CEP) ... Ariz., March 30 First Choice Professionals, LLC., ... (Nasdaq: TIBX ), to provide healthcare ... a unified solution. FCP,s renowned healthcare integration group ...
... Recognized for Efficient Energy Performance KENILWORTH, N.J., March ... has named Schering-Plough Corporation as a 2009 ENERGY ... management and reductions in greenhouse gas emissions. The ... ceremony in Washington, D.C., on March 31, 2009.In ...
... Equipment,s LC Sprint reusable nebulizer and TREK S portable compressor ... of "ER" that will air Thursday at 9pm on NBC. ... of "ER," including George Clooney and Julianna Margulies, so the ... PARI nebulizers have been used on the show to highlight ...
... 30 Genaera Corporation (Nasdaq: GENR ) ... conserve existing cash resources in order to maintain the ... the first-in-class, highly selective inhibitor of PTP1B and Genaera,s ... diabetes and obesity, and explore strategic alternatives. The ...
... 30 Folding carton specialist Benson,Group, UK packaging company ... into the pharmaceutical labels sector with the purchase of ... and inspection,machine for its pharmaceutical-focused Medica Packaging business in ... customer demand as being the key driving factor behind,the ...
... MONDAY, March 30 (HealthDay News) -- Babies who gain weight ... more prone to obesity as toddlers, Harvard researchers report. , ... much younger," said study author Dr. Elsie M. Taveras. "Even ... start guiding parents about how to prevent rapid weight gain ...
Cached Medicine News:Health News:First Choice Professionals and TIBCO Announce Strategic Partnership to Advance Healthcare Integration 2Health News:EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year 2Health News:EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year 3Health News:PARI's LC Sprint & TREK S Featured in 'ER' Final Episode on NBC Thursday 2Health News:Genaera Corporation Implements Cash Conservation Plan 2Health News:Benson Group Moves into Pharma Labels Sector 2Health News:Benson Group Moves into Pharma Labels Sector 3Health News:Rapid Infant Weight Gain Linked to Childhood Obesity 2
... The LT-Cage device ... balance with significantly less ... endplates. Medtronic Sofamor Danek's ... designed to easily and ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool....
Adjust-A-Tip cautery....
Medicine Products: